Aravive
safety profile consistent with the established safety profile for nab or underlying disease in study | Aravive
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
30 of 39
Related slides by other companies
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
Valneva
IPO
April 2021
was well tolerated in phase safety profile within the expected range for an inactivated vaccine ans | Valneva
Mink Therapeutics
Investor Day
November 2022
| Mink Therapeutics
Erasca
Investor Presentation
January 2024
demonstrated a favorable manageable safety profile | Erasca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights